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Abstract
Introduction: Risk stratification in patients undergoing extracorporeal membrane oxygenation (ECMO) support after
cardiovascular surgery remains challenging, because data on specific outcome predictors are limited. Serum
butyrylcholinesterase demonstrated a strong inverse association with all-cause and cardiovascular mortality in
non-critically ill patients. We therefore evaluated the predictive value of preoperative serum butyrylcholinesterase
levels in patients undergoing venoarterial ECMO support after cardiovascular surgery.
Methods: We prospectively included 191 patients undergoing venoarterial ECMO therapy after cardiovascular surgery
at a university-affiliated tertiary care center in our registry.
Results: All-cause and cardiovascular mortality were defined as primary study end points. During a median follow-up
time of 51 months (IQR, 34 to 71) corresponding to 4,197 overall months of follow-up, 65% of patients died. Cox
proportional hazard regression analysis revealed a significant and independent inverse association between
higher butyrylcholinesterase levels and all-cause mortality with an adjusted hazard ratio (HR) of 0.44 (95% CI,
0.25 to 0.78; P = 0.005), as well as cardiovascular mortality, with an adjusted HR of 0.38 (95% CI, 0.21 to 0.70; P= 0.002),
comparing the third with the first tertile. Survival rates were higher in patients within the third tertile of butyrylcholinesterase
compared with patients within the first tertile at 30 days (68% versus 44%) as well as at 6 years (47% versus 21%).
Conclusions: The current study revealed serum butyrylcholinesterase as a strong and independent inverse predictor
of all-cause and cardiovascular mortality in patients undergoing venoarterial ECMO therapy after cardiovascular
surgery. These findings advance the limited knowledge on risk stratification in patients undergoing ECMO support
and represent a valuable addition for a comprehensive decision making before ECMO implantation.
Introduction
Extracorporeal membrane oxygenation (ECMO) is an
established therapeutic option for circulatory assistance in
patients with cardiogenic shock refractory to conventional
medical therapies after cardiovascular surgery [1]. How-
ever, long-term prognosis in this patient population re-
mains poor, and risk stratification, challenging, because
data on specific outcome predictors are limited [2].
Serum butyrylcholinesterase previously demonstrated
a strong inverse association with all-cause and cardio-
vascular mortality in a community-based population, as
well as in patients with coronary artery disease [3,4]. Al-
though butyrylcholinesterase was discovered more than
80 years ago [5], the precise physiological function is still
widely unknown. Because butyrylcholinesterase catalyzes
the hydrolysis of choline esters, including several muscle
relaxants [6], the previous scientific interest has been re-
duced to its impact on neuromuscular blockade after the
use of muscle relaxants in surgical patients over recent
years [7-9].
However, based on its remarkable predictive value for
mortality in noncritically ill patient populations [3,4], we
propose that butyrylcholinesterase might be a powerful
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predictor for clinical outcome in patients undergoing
ECMO therapy. Nevertheless, to the best of our know-
ledge, no such data exist from previous investigations.
We therefore analyzed the impact of preoperative serum
butyrylcholinesterase levels on cardiovascular and all-
cause mortality in patients undergoing venoarterial
ECMO support after cardiovascular surgery.
Materials and methods
Study population
We prospectively enrolled all patients undergoing venoar-
terial ECMO support after cardiovascular surgery between
February 2002 and December 2009 at the Vienna General
Hospital, a university-affiliated tertiary care center in our
registry, as previously published [10]. No exclusion criteria
were applied. The study protocol was reviewed and ap-
proved by the Ethics Committee of the Medical University
of Vienna and conforms to the Declaration of Helsinki; all
patients admitted to the Medical University of Vienna
provided written consent at hospital admission. The
ECMO circuit consisted of a centrifugal pump console
(Bio-Console560; Medtronic, New York, NY, USA)
with a hollow-fiber membrane oxygenator (Affinity-
NTTM; Medtronic). An experienced perfusionist and
the on-shift intensive care physician routinely serviced the
ECMO circuit once daily. The circuit was changed if blood
oxygenation declined sharply or if significant fibrin depos-
ition or clots were present. Under ECMO therapy, lungs
were ventilated at peak airway pressures <25 cmH2O,
physiologic respiratory tidal volumes (6 to 8 ml/kg), a re-
spiratory rate (≤10/min), and the fractional inspired
oxygen (FiO2) was reduced to 0.3. FiO2 was adjusted
by using the ECMO circuit to maintain a PO2 between
80 and 100 mm Hg. A more-detailed description regard-
ing ECMO management was previously published [10].
Clinical definitions and study end points
Cardiovascular risk factors were recorded according to
the respective guidelines. Determination of serum butyr-
ylcholinesterase activity is part of a routine laboratory
test, performed in all patients at time of admission at
the Vienna General Hospital. Serum butyrylcholinester-
ase was measured according to local laboratory standard
procedures by using an enzyme-kinetic assay with
butyrylthiocholine-iodide as substrate in serum at 25°C
[11]. The simplified acute physiology score (SAPS) II
score [12] was recorded at the time of ICU admission,
and the European System of Cardiac Operative Risk
Evaluation (EuroSCORE) was computed as previously
described [13]. All-cause and cardiovascular mortality
were selected as primary study end points and obtained
by screening the national register of death, including
screening for the cause of death (according to the
International Classification of Diseases, 10th Revision).
Statistical analysis
Discrete data were presented as count and percentage
and analyzed by using a χ2 test. Continuous data were
presented as median and interquartile range (IQR) and
compared by using analysis of variance (ANOVA). Their
association with butyrylcholinesterase was assessed by
using Spearman-Rho correlation coefficient. Cox propor-
tional hazard regression analysis was applied to assess
the effect of butyrylcholinesterase on survival. Therefore,
butyrylcholinesterase was stratified into tertiles, and the
results are presented as the hazard ratio (HR) for com-
parison of the 3rd tertile with the 1st tertile. To account
for potential confounding effects, we adjusted for estab-
lished risk factors including age, sex, SAPS II, left ven-
tricular function, ECMO duration, hypertension, diabetes,
hypercholesterolemia, estimated glomerular filtration rate
(eGFR), and albumin. GFR was calculated by using the
Cockcroft-Gault formula. Collinearity within the multi-
variate model was tested by using the variance inflation
factor and indicated no significant collinearity.
The impact of butyrylcholinesterase on survival was
further analyzed by using confounder-adjusted survival
curves, adjusted for all aforementioned variables in the
confounder model. Kaplan-Meier analysis (log-rank test)
was applied to verify the time-dependent discriminative
power of butyrylcholinesterase, and results were pre-
sented after 1 month, 1 year, and 6 years (reflecting the
75% percentile of the follow-up period). Continuous var-
iables were log transformed before entering analysis.
Two-sided P values <0.05 were used to indicate statis-
tical significance. The STATA11 software package and
SPSS 17.0 were used for all analyses.
Results
We enrolled 191 ECMO patients with a median age of
62 years (IQR, 51 to 69 years) undergoing ECMO after car-
diovascular surgery into our study. ECMO support was ini-
tiated in 56 patients after valve surgery, in 26 after coronary
artery bypass graft (CABG) surgery, in 38 after combined
CABG-valve surgery, in 39 patients after cardiac transplant-
ation, and in 32 after other cardiovascular surgeries.
ECMO implantation was performed femoral-femoral
in 82% of patients, subclavian-femoral in 10% of pa-
tients, and central-femoral in 8% of patients. In 14 pa-
tients (7%), ECMO implantation was performed under
cardiac massage. Indications for ECMO support were
weaning failure from cardiopulmonary bypass (58%),
postoperative cardiogenic shock (25%), immediate post-
transplant cardiac graft failure (6%), postoperative respira-
tory failure (2%), postoperative bleeding/tamponade with
cardiogenic shock (7%), and miscellaneous conditions (3%).
ECMO-related- complications occurred in 25% of patients.
In detail, major bleeding was observed in 22 patients
(12%), defined as cannulation-site bleeding requiring
Distelmaier et al. Critical Care 2014, 18:R24 Page 2 of 7
http://ccforum.com/content/18/1/R24
transfusion or surgical intervention, significant thrombus
formation within the ECMO circuit in 13 patients (7%),
and leg ischemia including compartment syndrome in 12
patients (6%). Detailed baseline characteristics are dis-
played in Table 1. Correlations for continuous variables
and their association with cholinesterase, assessed by
using Spearman–Rho correlation coefficient, are pre-
sented in Table 2.
Levels of butyrylcholinesterase showed a significant
correlation with albumin, hypertension, hypercholester-
olemia, and weak but significant inverse associations
with EuroSCORE, ECMO duration, aspartate amino-
transferase (ASAT), and γ-glutamyltransferase (Table 1).
During a median follow-up time of 51 months (IQR, 34
to 71 months) corresponding to 4,197 overall months of
follow-up, 65% of patients (n = 125) died. Of these, 89%
of deaths had cardiovascular causes.
Survival analysis
We identified a significant inverse association between
higher butyrylcholinesterase levels and all-cause mortality
with a crude hazard ratio (HR) of 0.50 (95% CI, 0.32 to
0.78; P = 0.002) as well as cardiovascular mortality with a
crude HR of 0.44 (95% C,I 0.27 to 0.71; P = 0.001) when
comparing the third with the first tertile. This effect was
even more pronounced after adjustment for potential con-
founders with an adjusted HR of 0.44 (95% CI, 0.25 to
0.78; P = 0.005) for all-cause mortality and an adjusted HR
of 0.38 (95% CI, 0.21 to 0.70; P = 0.002) for cardiovascular
mortality. The results of the Cox regression analysis
remained virtually unchanged after adjustment for other
established risk factors (that is, previous coronary artery
disease, chronic obstructive pulmonary disease, ECMO
implantation, under cardiac massage, and ECMO-related
complications (data not shown) and therefore not in-
cluded in the final multivariate model.
Adjusted survival curves demonstrated a significant
decrease of 30-day (P = 0.017; Figure 1A) and long-term
(P = 0.019; Figure 1B) all-cause mortality, as well as a
significant decrease of 30-day (P = 0.008; Figure 1C) and
long-term (P = 0.007; Figure 1D) cardiovascular mortal-
ity with increasing serum levels of butyrylcholinesterase.
Table 1 Baseline characteristics of total ECMO study population (n = 191) and for tertiles of butyrylcholinesterase
Total study population
(n = 191)
1st tertile 2nd tertile 3rd tertile P value*
Tertiles of cholinesterase, kU/l (IQR) 5.04 (3.38-6.31) 2.81 (2.35-3.39) 5.04 (4.60-5.04) 7.45 (6.57-8.40) ————
Age, median years (IQR) 62 (51–69) 65 (52–70) 61 (50–70) 62 (52–69) 0.697
Male sex n (%) 136 (71%) 48 (75%) 44 (68%) 44 (71%) 0.613
SAPS II at ICU admission, n (%) 44 (31–60) 47 (37–57) 47 (33–58) 47 (31–61) 0.790
EuroSCORE (additive), points (IQR) 10 (6–13) 12 (8–13) 10 (6–14) 8 (5–11) 0.017
Procedure duration, hour (IQR) 7.2 (4.8-9.0) 7.0 (4.7- 8.5) 7.1 (5.3-9.0) 7.8 (4.8-9.5) 0.265
ECMO duration, median days (IQR) 4 (2–6) 6 (3–7) 5 (2–7) 4 (2–7) 0.279
Time on mechanical ventilation,
median days (IQR)
11 (4–19) 9 (3–16) 13 (6–24) 10 (4–19) 0.427
IABP, n (%) 29 (15%) 9 (14%) 11 (17%) 9 (15%) 0.940
Hypertension, n (%) 86 (45%) 24 (38%) 24 (37%) 38 (61%) 0.008
Diabetes, n (%) 42 (22%) 12 (19%) 17 (26%) 13 (21%) 0.757
Hypercholesterolemia, n (%) 54 (28%) 11 (17%) 22 (34%) 21 (34%) 0.037
Coronary artery disease, n (%) 75 (42%) 25 (41%) 26 (43%) 24 (41%) 0.963
Left ventricular ejection fraction
30% to 44%, n (%) 32 (17%) 13 (20%) 10 (15%) 9 (15%) 0.383
<30%, n (%) 81 (42%) 28 (44%) 31 (48%) 22 (36%) 0.354
Creatinine, mg/dl (IQR) 1.36 (1.10–1.88) 1.56 (1.17-2.23) 1.47 (1.11-1.94) 1.25 (1.03-1.69) 0.245
Estimated GFR, ml/min/1.73 m2 (IQR) 57 (38–77) 53 (35–74) 58 (37–67) 64 (45–88) 0.045
Albumin, g/L (IQR) 36 (28–42) 28 (23–35) 37 (31–41) 42 (38–45) <0.001
ASAT, U/L (IQR) 39 (26–111) 48 (32–138) 48 (28–123) 31 (24–48) 0.345
ALAT, U/L (IQR) 32 (18—61) 34 (15–81) 36 (20–58) 29 (18–49) 0.486
Gamma-GT, U/L (IQR) 59 (33—121) 76 (28–151) 75 (39–149) 47 (31–88) 0.089
Continuous data are presented as median (interquartile range). *Tertiles of butyrylcholinesterase are compared by using ANOVA analysis. Categoric data are
analyzed by using a test for linear association (Mantel–Haenszel χ2 test). ECMO, extracorporeal membrane oxygenation; GFR, glomerular filtration rate estimated
by using Cockcroft-Gault formula; IABP, intraaortic balloon pump; SAPS II, simplified acute physiology score II.
Bold typefaces indicate statistical significance (P < 0.05).
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Survival was increased in patients within the third tertile
of butyrylcholinesterase compared with patients within
the first tertile after 30 days (68% versus 44%), after
1 year (55% versus 30%), and after 6 years (47% versus
21%). A similar trend was observed for cardiovascular
mortality.
Discussion
The current study demonstrates for the first time a
strong inverse association between serum butyrylcholin-
esterase levels and long-term mortality as well as short-
term mortality in patients undergoing veno-arterial
ECMO support following cardiovascular surgery. These
associations were even more pronounced after adjust-
ment for potential confounders.
Assessment of butyrylcholinesterase is an inexpensive,
easily available laboratory marker that is routinely mea-
sured in many centers at hospital admission. Our data
indicate that preoperative determination of serum butyr-
ylcholinesterase provides essential information regarding
the clinical outcome of patients requiring ECMO sup-
port. In regard of the high initial mortality of patients
undergoing ECMO support following cardiovascular sur-
gery [2,14-17], novel risk markers are critical for a more
accurate risk assessment prior to surgery. Particularly,
the strong predictive value for 30-day mortality as well
as long-term mortality indicates the importance of
serum butyrylcholinesterase for risk stratification. Con-
sidering the Kaplan Meier plots (Figure 1), the protective
value of serum butyrylcholinesterase does not simply
persist after 30 days but even increases over the observa-
tion period suggesting a sustained effect of butyrylcho-
linesterase on clinical outcome. Butyrylcholinesterase
activity might be regarded as surrogate parameter for
the patients’ general clinical conditions [18,19]. In elderly
patients undergoing elective total hip replacement low
preoperative serum butyrylcholinesterase activity has
been identified to predict poor postoperative outcome
[20]. The authors identified an inverse correlation of bu-
tyrylcholinesterase with total bilirubin and international
normalized ratio, which is in line with prior studies sug-
gesting low butyrylcholinesterase activity as surrogate
marker for impaired liver synthesis and coagulation
[3,21,22]. This association might be of major clinical
relevance, considering that bleeding events are not only
the most frequent ECMO-related complications but also
the one with the greatest impact on mortality [23]. Pa-
tients requiring ECMO support represent a highly fragile
population that is exposed to a strong ECMO-related
systemic inflammatory response [24]. It is tempting to
speculate that ECMO patients with decreased serum bu-
tyrylcholinesterase levels might have an increased vul-
nerability to stressors associated with ECMO support,
due to reduced physiological reserves. However, as the
exact function of serum butyrylcholinesterase is mainly
unknown, the underlying pathophysiological mechanism
has to be elucidated by future studies.
The enzyme butyrylcholinesterase is synthesized and
secreted into blood by the liver and has been found to
be positively associated with cardiovascular disease risk
factors, including serum lipids, obesity, and hypertension
[3,4]. In accordance with these data, we confirmed a sig-
nificant correlation between serum butyrylcholinesterase
levels and history of hypertension. Furthermore, we veri-
fied a close correlation of serum butyrylcholinesterase
with albumin, which might be explained by the binding
Table 2 Correlation table for continuous variables and their association with cholinesterase assessed by using
Spearman–Rho correlation coefficient
Total study population (n = 191) Correlation, r P value
Age, median years (IQR) 62 (51–69) −0.05 0.535
SAPS II at ICU admission, n (%) 44 (31–60) −0.05 0.530
EuroSCORE (additive), points (IQR) 10 (6–13) −0.23 0.001
Procedure duration, hours (IQR) 7.2 (4.8-9.0) 0.12 0.113
ECMO duration, median days (IQR) 4 (2–6) −0.17 0.016
Time on mechanical ventilation, median days (IQR) 11 (4–19) 0.06 0.419
Creatinine, mg/dl (IQR) 1.36 (1.10–1.88) −0.12 0.098
Estimated GFR, ml/min/1.73 m2 (IQR) 57 (38–77) 0.11 0.138
Albumin, g/L (IQR) 36 (28–42) 0.59 <0.001
ASAT, U/L (IQR) 39 (26–111) −0.20 0.005
ALAT, U/L (IQR) 32 (18—61) −0.03 0.734
γ-GT, U/L (IQR) 59 (33—121) −0.14 0.049
Continuous data are presented as median (interquartile range), and their association with cholinesterase was assessed by using Spearman–Rho correlation
coefficient. ECMO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump; GFR, glomerular filtration rate estimated by using Cockcroft-Gault
formula; SAPS II, simplified acute physiology score II.
Bold typefaces indicates statistical significance (P < 0.05).
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of butyrylcholinesterase to albumin [25]. However, after
adjustment for hypertension and albumin the association
of butyrylcholinesterase with mortality was even more
distinct.
A potential limitation of our study is that our data re-
flect the experience of a single center. Furthermore, al-
though our number of long-term survivors and median
follow-up evaluated is among the highest reported to
date, it might still not be sufficient to draw definitive
conclusions.
We identified serum butyrylcholinesterase as a strong
and independent inverse predictor of all-cause mortality
and cardiovascular mortality in patients undergoing
veno-arterial ECMO therapy following cardiovascular
surgery. Preoperative risk factors such as advanced age,
diabetes, adiposity, renal insufficiency, severe metabolic
acidosis, chronic obstructive pulmonary disease, previous
cardiac surgery, poor left-ventricular ejection fraction,
and systolic blood pressure <90 mmHg have been iden-
tified as independent predictors for outcome in patients
requiring ECMO support following cardiovascular sur-
gery [10,14,15,26,27]. The current study complements
the knowledge on risk stratification in these patients
and represents a valuable addition for a comprehensive
decision-making prior to ECMO implantation. These
results are particularly compelling, because measure-
ment of such a long-known biomarker as butyrylcholines-
terase is inexpensive and routinely available in most
laboratories. However, the exact pathophysiological mech-
anism underlying these associations has to be further elu-
cidated. Considering the poor outcome of these patients,
[2] an accurate preoperative risk prediction might be es-
sential to reduce the unregulated use of ECMO which is
associated with a disproportionately increase of health
Figure 1 Confounder-adjusted survival curves of all-cause and cardiovascular mortality according to tertiles of butyrylcholinesterase.
Adjusted survival curves demonstrated a significant decrease of 30-day (A, P= 0.017) and long-term (B, P= 0.019) all-cause mortality, as well as a significant
decrease of 30-day (C, P= 0.008) and long-term (D, P= 0.007) cardiovascular mortality with increasing serum levels of butyrylcholinesterase.
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care costs and resources consumption. Therefore, the de-
velopment of a clinically applicable mortality prediction
score, including all of these clinical determinants as well
as serum butyrylcholinesterase, has to be addressed by fu-
ture studies. So far, ECMO patients with low butyrylcho-
linesterase levels should be considered at least as high-risk
patients that may benefit from an intensified treatment
and close check-ups after hospital discharge.
Conclusions
The present study identified serum butyrylcholinester-
ase as a strong and independent inverse predictor of
all-cause and cardiovascular mortality in patients under-
going veno-arterial ECMO therapy following cardiovascu-
lar surgery. These findings advance the limited knowledge
on risk stratification in patients undergoing ECMO sup-
port and represent a valuable addition for a comprehen-
sive decision-making prior to ECMO implantation.
Key messages
 High mortality in patients undergoing venoarterial
ECMO support after cardiovascular surgery.
 Preoperative serum butyrylcholinesterase levels are
a strong and independent inverse predictor of all-cause
mortality and cardiovascular mortality in patients
undergoing ECMO therapy after cardiovascular
surgery.
 Preoperative determination of serum
butyrylcholinesterase levels might provide a
valuable addition for a comprehensive risk-stratification
before ECMO implantation.
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